Evidence-Based Diabetes Management
Evidence-Based Immunology and Infectious Disease
Evidence-Based Respiratory Care
Subscribe for FREE
AHIP Medicare Medicaid
AJMC Live Meeting - Oncology
AMCP Fall 2013
AMCP Spring 2014
ASHP Midyear 2013
Joslin Diabetes Innovation
NAMCP Spring 2013
NAMCP Spring 2014
Information for AJMC
Information for AJPB
Call for Papers
Submit / Track a Manuscript
Information for Reviewers
Acute Coronary Syndrome
Mantle Cell Lymphoma
Value-Based Insurance Design
Medical Homes and Cost and Utilization Among High-Risk Patients | Page 3
March 24, 2014
Susannah Higgins, MS; Ravi Chawla, MBA; Christine Colombo, MBA; Richard Snyder, MD; and Somesh Nigam, PhD
PDF is available on the last page.
<< Previous Page (2)
Issue: March 2014
STABLE Results: Warfarin Home Monitoring Achieves Excellent INR Control
Grace DeSantis, PhD; Jackie Hogan-Schlientz, RN, BSN; Gary Liska, BS; Shari Kipp, BS; Ramarion Sallee; Mark Wurster, MD; Kenneth Kupfer, PhD; and Jack Ansell, MD
Real-world retrospective analysis of over 29,000 patients performing INR home monitoring for warfarin therapy shows excellent time in therapeutic range.
Do Strict Formularies Replicate Failure for Patients With Schizophrenia?
Dana P. Goldman, PhD; Riad Dirani, PhD; John Fastenau, MPH, RPh; and Ryan M. Conrad, PhD
This study measures the impact of Medicaid formulary restrictions on the rate at which patients who failed on a drug therapy for schizophrenia return to the same therapy.
The Economics of Resistant Pathogens and Antibiotic Innovation
Michael R. McKellar, BA; Michael E. Chernew, PhD; and A. Mark Fendrick, MD
This commentary discusses why antibiotics and the treatment of infectious diseases present a special case for pharmaceutical development, pricing, and appropriate utilization.
Click for Full Issue
More on AJMC.COM
Is All “Skin in the Game” Fair Game? The Problem With “Non-Preferred” Generics
Effective Implementation of Collaborative Care for Depression: What Is Needed?
13% of Hospital Costs Motivated by Malpractice Fear
Study Questions Screening Policy on Mammographically-Dense Breasts in Women
In AJMC, Oster & Fendrick Challenge Designation of High-Value Generic Drugs as “Non-Preferred” Based on Cost, Not Evidence
Terms & Conditions
| Copyright HCPLive 2006-2014 | Intellisphere, LLC. All Rights Reserved.
Specialty Pharmacy Times